| Symbol | BHVN |
|---|---|
| Name | BIOHAVEN LTD. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 215 CHURCH STREET, NEW HAVEN, Connecticut, 06510, United States |
| Telephone | +1 203 404-0410 |
| Fax | — |
| — | |
| Website | https://www.biohaven.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Additional info from NASDAQ: |
Director Mehta Kishan 🟡 adjusted position in 0 shares of Biohaven Ltd. (BHVN) Transaction Date: Mar 17, 2026 | Filing ID: 000003
Read moreBiohavens Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Read moreBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Read moreBiohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Read moreBiohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Read moreBiohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
Read moreBiohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Read moreBiohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
Read moreBiohaven Announces Pricing of $175 Million Public Offering of Common Shares
Read more